Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury

Lin DU; Feng GAO; Jie ZHANG

doi:10.1007/s11655-021-3300-2

Your Location：

Home >

Browse articles >

Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury

Clinical Experience | Updated：2021-09-01

- Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury
- Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury
- Chinese Journal of Integrative Medicine 2021年27卷第8期页码：621-625
- Affiliations：
  
  Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing(100029), China
- Author bio：
  
  Prof. ZHANG Jie, E-mail: zhangjie4155@sina.com
- Funds：
  
  Beijing Chinese Medicine Science and Technology Development Fund(JJ2018-02)
- DOI：10.1007/s11655-021-3300-2
  中图分类号：
- 纸质出版日期：2021-08-01，
  
  网络出版日期：2021-06-08，
  
  录用日期：2020-12-09
Scan for full text
Lin DU, Feng GAO, Jie ZHANG. Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury[J]. Chinese Journal of Integrative Medicine, 2021,27(8):621-625.

Lin DU, Feng GAO, Jie ZHANG. Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury[J]. Chinese Journal of Integrative Medicine, 2021,27(8):621-625.
Lin DU, Feng GAO, Jie ZHANG. Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury[J]. Chinese Journal of Integrative Medicine, 2021,27(8):621-625. DOI： 10.1007/s11655-021-3300-2.

Lin DU, Feng GAO, Jie ZHANG. Effect of Weikang Capsule (胃康胶囊) on Aspirin-Related Gastric and Small Intestinal Mucosal Injury[J]. Chinese Journal of Integrative Medicine, 2021,27(8):621-625. DOI： 10.1007/s11655-021-3300-2.

摘要

Abstract

Objective:

To investigate the effects of Weikang Capsule (胃康胶囊

WKC) on aspirin-related gastric and small intestinal mucosal injury by magnetically controlled capsule endoscopy (MCCE).

Methods:

Patients taking enteric-coated aspirin aged 40–75 years were enrolled in Beijing Anzhen Hospital

Capital Medical University from January 2019 to December 2019. The patients continued taking aspirin Tablet (100 mg per day) and underwent MCCE before and after 1-month combined treatment with WKC (0.9 g per time orally

3 times per day). The gastrointestinal symptom score

gastric Lanza score

the duodenal

jejunal and ileal mucosal injury scores were used to evaluate the gastrointestinal injury before and after treatment. Adverse events including nausea

vomiting

abdominal pain

abdominal distension

abdominal discomfort

dizziness

or headache during MCCE and combined treatment were observed and recorded.

Results:

Twenty-two patients (male/female

13/9) taking enteric-coated aspirin aged 59.5±11.3 years with a duration of aspirin use of 28.0 (1.0

48.0) months were recruited. Compared with pre-treatment

the gastrointestinal symptom rating scale scores

gastric Lanza scores

and duodenal mucosal injury scores were significantly reduced after 1-month WKC treatment (

0.05)

and jejunal and ileal mucosal injury scores showed no obvious change. No adverse events occurred during the trial.

Conclusions:

WKC can alleviate gastrointestinal symptoms

as well as gastric and duodenal mucosal injuries

in patients taking enteric-coated aspirin; it does not aggravate jejunal or ileal mucosal injury

which may be an effective alternative for these patients (Clinical trial registry No. ChiCTR1900025451).

关键词

Keywords

Weikang Capsulemagnetically controlled capsule endoscopyenteric-coated aspiringastric mucosal injurysmall intestinal mucosal injuryChinese medicine

references

Iwamoto J, Saito Y, Honda A, Matsuzaki Y. Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy. World J Gastroenterol 2013;19:1673-1682.

Hiraishi H, Shimada T, Terano A. Involvement of oxidative stress in the pathogenesis of NSAID-induced gastric mucosal damage. J Gastroenterol 2000;35:567-569.

Endo H, Sakai E, Taniguchi L, Kessoku T, Komiya Y, Ezuka A, et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc 2014;80:826-834.

Chen WC, Lin KH, Huang YT, Tsai TJ, Sun WC, Chuah SK, et al. The risk of lower gastrointestinal bleeding in low-dose aspirin user. Aliment Pharmacol Ther 2017;45:1542-1550.

Wallace JL. Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drugenteropathy. World J Gastroenterol 2013;19:1861-1876.

Lué A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: balancing risks and benefits.World J Gastroenterol 2016;22:10477-10481.

Chinese Expert Recommendation on Prevention of Gastrointestinal Injury Related to Antithrombotic Therapy group. The Chinese expert recommendation on prevention of gastrointestinal injury related to antithrombotic therapy.Chin J Intern Med (Chin) 2016;55:564-567.

Yasuda S, Nakao K, Nishimura K, Miyamoto Y, Sumita Y, Shishido T, et al. The current status of cardiovascular medicine in Japan—analysis of a large number of health records from a nationwide claim-based database, JROADDPC. Circ J 2016;80:2327-2335.

Endo H, Sakai E, Kato T, Umezawa S, Higurashi T, Ohkubo H, et al. Small bowel injury in low-dose aspirin users. J Gastroenterol 2015;50:378-386.

Geriatrics Branch of Chinese Medical Association, Editorial Board of Chinese Journal of Internal Medicine, Editorial Board of Chinese Journal of Geriatrics. Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement. Chin J Intern Med (Chin) 2017;56:68-80.

Chen X, Gao F, Zhang J. Screening for gastric and small intestinal mucosal injury with magnetically controlled capsule endoscopy in asymptomatic patients taking enteric-coated aspirin. Gastroenterol Res Pract 2018;2018:2524689.

Lanza FK, Collaku A, Liu DJ. Endoscopic comparison of gastroduodenal injury with over-the-counter doses of new fast-dissolving ibuprofen and paracetamol formulations: a randomized, placebo-controlled, 4-way crossover clinical trial. Clin Exp Gastroenterol 2018;11:169-177.

Gao F, Chen X, Zhang J. Prevalence of gastric and small intestinal mucosal injury in elderly patients taking enteric-coated aspirin by magnetically controlled capsule endoscopy. Gastroenterol Res Pract 2019;2019:1582590.

Suzuki T, Masui A, Nakamura J, Shiozawa H, Aoki J, Nakae H, et al. Yogurt containing Lactobacillus gasseri mitigates aspirininduced small bowel injuries: a prospective, randomized, double-blind, placebo-controlled trial. Digestion 2017;95:49-54.

Ding RF, Guo YH, Han WP, Wang AY, Xie LP, Zhao PC.Preventive effects of Jinghua Weikang Capsule on NSAID-induced injury to the mucosa of the small intestine: an experimental research. Chin J Integr Tradit West Med (Chin)2013;33:522-525.

Fan TY, Feng QQ, Jia CR, Fan Q, Li CA, Bai XL. Protective effect of Weikang Decoction and partial ingredients on model rat with gastric mucosa ulcer. World J Gastroenterol 2005;11:1204-1209.

Takeuchi K, Satoh H. NSAID-induced small intestinal damage—roles of various pathogenic factors. Digestion 2015;91:218-232.

Otani K, Tanigawa T, Watanabe T, Shimada S, Nadatani Y, Nagami Y, et al. Microbiota plays a key role in non-steroidal anti-inflammatory drug-induced small intestinal damage.Digestion 2017;95:22-28.

Watanabe T, Tanigawa T, Nadatani Y, Otani K, Machida H, Okazaki H, et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr 2011;48:117-121.

Tai FWD, McAlindon ME. NSAIDs and the small bowel.Curr Opin Gastroenterol 2018;34:175-182.

Nadatani Y, Watanabe T, Suda W, Nakata A, Matsumoto Y, Kosaka S, et al. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii. Sci Rep 2019;9:17490.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

Immunoregulatory and Anti-cancer Activities of Combination Treatment of Novel Four-Herb Formula and Doxorubicin in 4T1-Breast Cancer Bearing Mice

TRAIL and Celastrol Combinational Treatment Suppresses Proliferation, Migration, and Invasion of Human Glioblastoma Cells via Targeting Wnt/β-Catenin Signaling Pathway